You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Second- and third-generation ALK inhibitors for non-small cell lung cancer
|
|---|---|
| Published in |
Journal of Hematology & Oncology, March 2016
|
| DOI | 10.1186/s13045-016-0251-8 |
| Pubmed ID | |
| Authors |
Jingjing Wu, John Savooji, Delong Liu |
| Abstract |
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Taiwan | 1 | <1% |
| Unknown | 121 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 16% |
| Student > Ph. D. Student | 15 | 12% |
| Other | 13 | 11% |
| Student > Master | 13 | 11% |
| Student > Doctoral Student | 11 | 9% |
| Other | 18 | 15% |
| Unknown | 33 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 21% |
| Biochemistry, Genetics and Molecular Biology | 23 | 19% |
| Agricultural and Biological Sciences | 11 | 9% |
| Chemistry | 9 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Other | 5 | 4% |
| Unknown | 40 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2016.
All research outputs
#20,335,770
of 22,880,691 outputs
Outputs from Journal of Hematology & Oncology
#1,035
of 1,192 outputs
Outputs of similar age
#252,867
of 299,427 outputs
Outputs of similar age from Journal of Hematology & Oncology
#28
of 34 outputs
Altmetric has tracked 22,880,691 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,192 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,427 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.